scholarly journals Association of the Vitamin D Metabolism Gene CYP27B1 With Type 1 Diabetes

Diabetes ◽  
2007 ◽  
Vol 56 (10) ◽  
pp. 2616-2621 ◽  
Author(s):  
R. Bailey ◽  
J. D. Cooper ◽  
L. Zeitels ◽  
D. J. Smyth ◽  
J. H.M. Yang ◽  
...  
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Vitamin D Metabolism ◽  
Metabolism Gene

scholarly journals Evaluation of Vitamin D Metabolism in Patients with Type 1 Diabetes Mellitus in the Setting of Cholecalciferol Treatment

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3873
Author(s):  
Alexandra Povaliaeva ◽  
Ekaterina Pigarova ◽  
Artem Zhukov ◽  
Viktor Bogdanov ◽  
Larisa Dzeranova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Controlled Study ◽  
Affinity Constant ◽  
Vitamin D Metabolites ◽  
Vitamin D Metabolism ◽  
Vitamin D Levels

In this prospective controlled study, we examined 25 adults with adequately controlled (HbA1c level < 8.0%) type 1 diabetes mellitus (T1DM) and 49 conditionally healthy adults, intending to reveal the diversity of vitamin D metabolism in the setting of cholecalciferol intake at a therapeutic dose. All patients received a single dose (150,000 IU) of cholecalciferol aqueous solution orally. Laboratory assessments including serum vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3 and 24,25(OH)2D3), free 25(OH)D, vitamin D-binding protein (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters were performed before the intake and on Days 1, 3 and 7 after the administration. The studied groups had no significant differences in baseline parameters except that the patients with diabetes showed higher baseline levels of free 25(OH)D (p < 0.05). They also lacked a correlation between the measured and calculated free 25(OH)D in contrast to the patients from the control group (r = 0.41, p > 0.05 vs. r = 0.88, p < 0.05), possibly due to the glycosylation of binding proteins, which affects the affinity constant for 25(OH)D. The elevation of vitamin D levels after the administration of cholecalciferol was comparable in both groups, with slightly higher 25(OH)D3 levels observed in the diabetes group throughout the study since Day 1 (p < 0.05). Overall, our data indicate that in patients with adequately controlled T1DM 25(OH)D3 levels and the therapeutic response to cholecalciferol is similar to that in healthy individuals.

No association between type 1 diabetes and genetic variation in vitamin D metabolism genes: a Danish study

2013 ◽  
Vol 15 (6) ◽  
pp. 416-421 ◽  
Author(s):  
Steffen U Thorsen ◽  
Henrik B Mortensen ◽  
Bendix Carstensen ◽  
Mogens Fenger ◽  
Betina H Thuesen ◽  
...  
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Genetic Variation ◽  
Vitamin D Metabolism ◽  
Danish Study

scholarly journals Dysregulation of the Intrarenal Vitamin D Endocytic Pathway in a Nephropathy-Prone Mouse Model of Type 1 Diabetes

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
John L. Fowlkes ◽  
R. Clay Bunn ◽  
Gael E. Cockrell ◽  
Lindsey M. Clark ◽  
Elizabeth C. Wahl ◽  
...  
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Target Genes ◽  
Diabetic Mouse ◽  
Endocytic Pathway ◽  
Diabetic Mice ◽  
Vitamin D Metabolism ◽  
25 Hydroxy Vitamin D ◽  
And Control

Microalbuminuria in humans with Type 1 diabetes (T1D) is associated with increased urinary excretion of megalin, as well as many megalin ligands, including vitamin-D-binding protein (VDBP). We examined the DBA/2J diabetic mouse, nephropathy prone model, to determine if megalin and VDBP excretion coincide with the development of diabetic nephropathy. Megalin, VDBP, and 25-hydroxy-vitamin D (25-OHD) were measured in urine, and genes involved in vitamin D metabolism were assessed in renal tissues from diabetic and control mice at 10, 15, and 18 weeks following the onset of diabetes. Megalin, VDBP, and 25-OHD were increased in the urine of diabetic mice. 1-α hydroxylase (CYP27B1) mRNA in the kidney was persistently increased in diabetic mice, as were several vitamin D-target genes. These studies show that intrarenal vitamin D handling is altered in the diabetic kidney, and they suggest that in T1D, urinary losses of VDBP may portend risk for intrarenal and extrarenal vitamin D deficiencies.

Potential role of vitamin D in the prevention and treatment of type 1 diabetes mellitus

2021 ◽  
Vol 70 (2) ◽  
pp. 91-105
Author(s):  
Elena V. Misharina ◽  
Mariya I. Yarmolinskaya ◽  
Elena I. Abashova
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Vitamin D Deficiency ◽  
Current Data ◽  
Vitamin D Metabolism ◽  
Immunomodulating Therapy

The incidence of type 1 diabetes mellitus is increasing worldwide, and the number of people with vitamin D deficiency in all age groups, including children and adolescents, is simultaneously growing in the world. Over the past decades, it has been found that vitamin D, in addition to participating in the regulation of calcium homeostasis and bone metabolism, has an anti-inflammatory and immunomodulatory effect. Epidemiological evidence suggests the involvement of vitamin D deficiency in the pathogenesis of type 1 diabetes mellitus. Polymorphisms in genes important for vitamin D metabolism also modulate the risk of type 1 diabetes mellitus. Several studies have evaluated the role of vitamin D as adjuvant immunomodulating therapy in patients with newly diagnosed type 1 diabetes mellitus. The purpose of this review is to present current data on the involvement of vitamin D in the pathogenesis of type 1 diabetes mellitus and to evaluate its role as a drug for the prevention of the disease and its use in treatment in addition to insulin therapy.

Genetic susceptibility to type 1 diabetes: genomic variants in the vitamin D pathway

2018 ◽  
Author(s):  
Joana Almeida ◽  
Dircea Rodrigues ◽  
Franscisco Carrilho ◽  
Joana Guimaraes ◽  
Manuel C Lemos
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Genetic Susceptibility ◽  
Genomic Variants

Vitamin D status and bone metabolism in adult patients with Type 1 diabetes mellitus

2019 ◽  
Author(s):  
Eleftheria Barmpa ◽  
Spyros Karamagiolis ◽  
Stelios Tigas ◽  
Georgios N Koukoulis ◽  
Alexandra Bargiota
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Bone Metabolism ◽  
Adult Patients ◽  
Vitamin D Status

Diabetes and osteoporosis

2011 ◽  
Vol 152 (29) ◽  
pp. 1161-1166 ◽  
Author(s):  
Zsuzsanna Valkusz
Keyword(s):  
Vitamin D ◽  
Type 1 Diabetes ◽  
Bone Mass ◽  
Fragility Fractures ◽  
Vitamin D Supplementation ◽  
Bone Collagen ◽  
Skeletal Changes ◽  
Glucagon Like Peptide 1 ◽  
Bone Quantity

Over the last decades a considerable amount of data has accumulated to indicate that metabolic and endocrine alterations of diabetes affect bone quantity and quality. These skeletal changes may increase the risk of bone fracture. There is strong evidence that in type 1 diabetes the decreased bone mass, lack of insulin and insulin-like growth factor-1, dysregulation of adipokines, and increased levels of proinflammatory cytokines are in the background of fragility fractures. In type 2 diabetes hyperinsulinemia, insulin resistance and increased body weight may result in an increase of bone mass; however, accumulation of advanced glycation end products within the bone collagen driven by glucotoxicity may increase the cortical porosity. There is a higher incidence of falls resulting from diabetes-related co-morbidities such as diabetic retinopathy, peripheral neuropathy, hypoglycemic episodes and sometimes from the medications. Vitamin D deficiency has special impact on glucose metabolism and the prevalence of diabetes. Vitamin D supplementation in childhood can decrease incidence of type 1 diabetes by 80%. The effect of thiazolidinediones, glucagon-like peptide-1 agonists and metformin, agents for treatment of diabetes open a new connection between bone, carbohydrate and fat metabolism. Orv. Hetil., 2011, 152, 1161–1166.

Sign in / Sign up

Export Citation Format

Share Document